<DOC>
	<DOCNO>NCT00200161</DOCNO>
	<brief_summary>Patients newly diagnose brain tumor call malignant glioma participate study see possible increase benefit temozolomide give radiation . A recent study show patient newly diagnose glioblastoma live longer treated temozolomide radiotherapy follow 6 month temozolomide patient treated radiotherapy alone . Patients receive standard low dose temozolomide radiation . After radiation , randomize receive either intense temozolomide continuous low dose temozolomide .</brief_summary>
	<brief_title>Temozolomide &amp; RT Followed Dose Dense v Temozolomide &amp; Retinoic Acid Pts w/Glioblastoma</brief_title>
	<detailed_description>This randomized phase II study test two different adjuvant temozolomide regimens patient newly diagnose glioblastoma multiforme . The goal study identify regimen would appropriate bring phase III trial compare standard dose regimen temozolomide recently report Stupp et al . New England Journal Medicine . Secondary goal study include : prospective analysis prognostic impact MGMT status generation preliminary data regard treatment strategy type malignant glioma . The decision regard treatment patient receive make randomly . Neither doctor select treatment patient receive . There reason believe dos may benefit treat brain tumor . After 6 month chemotherapy , assume brain tumor show sign growth , begin receive cis-retinoic acid . Cis retinoic acid show one study possibly prevent delay tumor recurrence .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Pathologic evidence malignant glioma . Tissue block unstained slide must available MGMT analysis . Age 1870 KPS &gt; 50 Granulocyte count &gt; 1.5 X 109/L Platelet count &gt; 99 X 109/L SGOT &lt; 2.5X upper limit normal ( ULN ) . Serum creatinine &lt; 2X ULN . Bilirubin &lt; 2X ULN . All patient must sign write informed consent . Any prior chemotherapy , radiotherapy biologic therapy glioma . Any prior experimental therapy glioma . Other concurrent active malignancy ( exception cervical carcinoma situ basal cell ca skin ) . Serious medical psychiatric illness would opinion investigator would interfere prescribed treatment . Pregnant breast feed woman . Refusal use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>